<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features and diagnosis of thyroid eye disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features and diagnosis of thyroid eye disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features and diagnosis of thyroid eye disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terry F Davies, MD, FRCP, FACE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Henry B Burch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid eye disease (also called Graves' orbitopathy or ophthalmopathy) is an autoimmune disease of the orbit and retro-ocular tissues occurring in patients with Graves' disease and rarely in patients with Hashimoto's thyroiditis. This topic review will provide an overview of the pathogenesis, clinical features, and diagnosis of thyroid eye disease. Treatment of this disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>In Graves' disease, the main autoantigen is the thyroid-stimulating hormone (TSH) receptor (TSHR), which is expressed primarily in the thyroid but is also expressed in adipocytes, fibroblasts, and a variety of additional sites [<a href="#rid1">1</a>]. The TSHR forms a functional complex with the insulin-like growth factor 1 (IGF-1) receptor [<a href="#rid2">2</a>]. TSHR antibodies, activated T cells, and macrophages play an important role in the pathogenesis of thyroid eye disease by activating orbital fibroblast and adipocyte TSHRs and IGF-1 receptors and initiating cellular expansion and orbital inflammation [<a href="#rid3">3</a>].</p><p>The volume of both the extraocular muscles and orbital connective tissue is increased, due to fibroblast proliferation, adipogenesis, inflammation, and the accumulation of hydrophilic glycosaminoglycans (GAG), mostly hyaluronic acid [<a href="#rid4">4,5</a>]. GAG secretion by fibroblasts is increased by thyroid-stimulating antibodies and activated T cells (via cytokine secretion), implying that both B and T cell activation are integral to this process. The accumulation of hydrophilic GAG in turn leads to fluid accumulation, muscle swelling  (<a class="graphic graphic_picture graphicRef59356" href="/z/d/graphic/59356.html" rel="external">picture 1</a>), and an increase in pressure within the orbit. These changes, together with the orbital adipogenesis, displace the eyeball forward, leading to extraocular muscle dysfunction and impaired venous drainage causing periorbital swelling  (<a class="graphic graphic_figure graphicRef72169" href="/z/d/graphic/72169.html" rel="external">figure 1</a> and <a class="graphic graphic_diagnosticimage graphicRef91472" href="/z/d/graphic/91472.html" rel="external">image 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid eye disease antigen: TSHR</strong> – The main autoantigen is the TSHR, which is expressed in orbital fibroblasts and forms a functional complex with the IGF-1 receptor.</p><p></p><p class="bulletIndent1">Immunization of mice with the TSHR induces orbital adipogenesis, an inflammatory infiltrate, and GAG accumulation [<a href="#rid6">6,7</a>]. TSHR messenger ribonucleic acid (mRNA) and protein can be detected in orbital fibroblasts and adipocytes, and preadipocytes from patients with thyroid eye disease may express more TSHR mRNA and produce more cyclic adenosine monophosphate (cAMP) in response to TSH than do similar cells from control individuals [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Although there is much evidence for extrathyroidal TSHR expression, the evidence that TSHR expression is greater in the orbital tissues of Graves' patients when compared with that found elsewhere is compelling. Hence, in addition to TSHR antigen directly activating the immune system, these observations suggest that TSHR expression in vivo is also enhanced by an external stimulus from the local inflammatory cells or directly by TSHR antibodies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of TSHR autoantibodies</strong> – TSHR antibodies play an important role in the pathogenesis of thyroid eye disease by activating orbital fibroblast and adipocyte TSHRs and the closely linked IGF-1 receptors and initiating an orbital inflammatory environment. </p><p class="bulletIndent1">There is significant crosstalk between the TSHR and the IGF-1 receptor in orbital fibroblasts, such that activation of the TSHR by TSHR autoantibodies can lead to IGF-1 receptor signal transduction, and a synergistic effect on GAG production occurs after activation of both receptors [<a href="#rid9">9</a>]. This crosstalk between the TSHR and the IGF-1 receptor forms the basis for the therapeutic use of <a class="drug drug_general" data-topicid="126630" href="/z/d/drug information/126630.html" rel="external">teprotumumab</a> (an IGF-1 monoclonal blocking antibody) in the treatment of thyroid eye disease [<a href="#rid10">10</a>]. Inhibition of the IGF-1 receptor ultimately results in apoptosis of orbital fibroblasts and adipocytes, and a subsequent reduction in proptosis [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease", section on 'Initial medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of T-cells</strong> – The following observations suggest that not just TSHR antibodies but T cells also play a role in the development of thyroid eye disease [<a href="#rid12">12,13</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In vitro studies of orbital tissue from patients with thyroid eye disease have shown that the infiltrating T cells are activated by orbital tissue fractions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orbital fibroblasts secrete GAG in response to cytokines such as interferon gamma and tumor necrosis factor (TNF)-alpha secreted by helper (CD4+) T cells of the Th1 type.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some of the muscle cells and fibroblasts express human leukocyte antigen (HLA) class II antigens, as seen on thyroid cells in patients with autoimmune thyroid disease, which suggests they can present antigen to T cells and resident dendritic cells, thereby serving to initiate or perpetuate the pathological process [<a href="#rid12">12-14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T cells isolated from orbital tissue (similar to those isolated from thyroid tissue) have limited V-region genotypes [<a href="#rid1">1</a>], and the same genotypes have been seen in the thyroid and orbital tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of genetics</strong> – The evidence for a genetic component to the pathogenesis of Graves' hyperthyroidism applies equally to the associated eye disease. A family history of Graves' disease or Hashimoto's disease, the presence of other autoimmune diseases in the patients and their relatives, and a high percentage of concordance in identical twins (depending on their age), all point toward a major genetic component in these disorders [<a href="#rid15">15</a>]. There are, however, no data confirming a distinct genetic risk that can be ascribed to thyroid eye disease.</p><p></p><p class="bulletIndent1">Certain HLA haplotypes have been associated with the presence of eye disease [<a href="#rid16">16</a>], but this has not been a common observation and appears more likely to be the same as for all patients with Graves' disease. The HLA gene region contains the genes most associated with Graves' disease itself.</p><p></p><p class="headingAnchor" id="H3469071310"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The epidemiology of thyroid eye disease in most studies of Graves' disease is not well defined. In a large series from a single Italian center, approximately 25 percent of patients with Graves' hyperthyroidism had clinically obvious eye involvement [<a href="#rid17">17</a>]. Most patients (20 percent) had mild disease, whereas 5.8 percent had moderate to severe disease. In another report from Europe, the estimated prevalence of all cases of thyroid eye disease ranged from 9 to 15 per 10,000 persons [<a href="#rid18">18</a>].</p><p>Enlargement of orbital muscles is evident in a larger proportion of patients on orbital imaging (eg, ultrasonography, computed tomography [CT], or magnetic resonance imaging [MRI]) [<a href="#rid19">19,20</a>]. In a study of MRI in 17 patients with no clinical findings of thyroid eye disease, 12 had extraocular muscle enlargement, which was bilateral in eight [<a href="#rid20">20</a>]. This type of study suggests that the majority of patients with Graves' disease have eye involvement; however, only a small percentage of individuals progress to clinically apparent eye disease. Preventing such progress may be a result of treating the hyperthyroidism early in the natural course of the disease.</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Several factors may increase the risk of thyroid eye disease in patients with Graves' disease [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – Graves' eye disease, like hyperthyroidism, is more common in females than males. However, males who have eye involvement are more likely to have an increase in severity during follow-up [<a href="#rid22">22</a>]. The explanation for this may be that males often have more severe Graves' disease for unclear reasons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – Cigarette smoking is a confirmed risk factor for thyroid eye disease [<a href="#rid21">21,23</a>]. As an example, in a case-control study from Australia, the odds ratio for eye disease was 2.22 in current smokers compared with never smoking [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Smoking is associated with an increase in the connective tissue volume of the orbit but not the extraocular muscle volumes [<a href="#rid24">24</a>]. How this might occur is not known, but direct toxic effects of smoke on the inflamed eyes are likely, and immunologic changes have been described in smokers that could affect the autoimmune process [<a href="#rid25">25</a>]. In addition, in vitro data suggest that cigarette smoke stimulates glycosaminoglycan (GAG) production and adipogenesis in a dose-dependent manner [<a href="#rid26">26</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radioiodine therapy</strong> – The type of treatment given for Graves' thyroid disease may be a risk factor for thyroid eye disease. In particular, radioiodine therapy is more likely to lead to the development or worsening of eye disease than antithyroid drug therapy or subtotal thyroidectomy. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease", section on 'Reversal of hyperthyroidism, if present'</a> and  <a class="medical medical_review" href="/z/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism", section on 'Thyroid eye disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyrotropin receptor antibodies, high levels</strong> – High titers of TSH receptor (TSHR) autoantibodies correlate with the presence and severity of extrathyroidal manifestations (thyroid eye disease and dermopathy) of Graves' disease. Even in patients with milder disease, there is an independent correlation between these autoantibodies and the prevalence and course of thyroid eye disease [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other risks</strong> – High serum cholesterol levels correlate with the development of thyroid eye disease [<a href="#rid28">28</a>], and statins have been shown to have a protective effect [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease", section on 'Other medical therapies'</a>.)</p><p></p><p class="bulletIndent1">Other possible risk factors for thyroid eye disease include advancing age [<a href="#rid21">21,22</a>], stress [<a href="#rid31">31</a>], and poorly controlled thyroid function [<a href="#rid32">32</a>]. There are case reports of reactivation (or new-onset) thyroid eye disease occurring after coronavirus 2019 (COVID-19) vaccination [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H4255905580"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Patients may have no ocular symptoms, may be distressed by the appearance of their eyes, or may be symptomatic. The major ocular symptoms include one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A gritty or foreign object sensation in the eyes</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive tearing that is often made worse by exposure to cold air, wind, or bright lights</p><p class="bulletIndent1"><span class="glyph">●</span>Eye or retro-ocular discomfort or pain</p><p class="bulletIndent1"><span class="glyph">●</span>Blurring of vision</p><p class="bulletIndent1"><span class="glyph">●</span>Diplopia</p><p class="bulletIndent1"><span class="glyph">●</span>Color vision desaturation</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of vision in severe cases</p><p class="bulletIndent1"><span class="glyph">●</span>Periorbital swelling</p><p></p><p>The characteristic signs of thyroid eye disease are proptosis (exophthalmos), conjunctival inflammation, and periorbital edema  (<a class="graphic graphic_picture graphicRef116687" href="/z/d/graphic/116687.html" rel="external">picture 2</a>). The degree of proptosis is dependent on the depth of the orbit and the degree of enlargement of the orbital muscles and orbital fibrous and fatty tissue. The proptosis may be symmetric, but is often asymmetric, and may be accompanied by a sensation of pressure behind the eyeballs. The proptosis may be partially masked by periorbital edema, which is a common accompaniment. In rare cases of very severe disease, there may be corneal ulceration from over exposure [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H2833716512"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>There is no disease marker for thyroid eye disease. In most patients, eye involvement occurs in the setting of current or past Graves' hyperthyroidism (low TSH, high free thyroxine [T4] and/or triiodothyronine [T3]), but in approximately 10 percent of patients, hyperthyroidism is absent [<a href="#rid4">4,35</a>]. Such patients are labeled as having "euthyroid" Graves' disease, but they may still have high serum thyroid autoantibody concentrations [<a href="#rid36">36,37</a>]. While some of these patients go on to develop typical Graves' hyperthyroidism over a period of years, some become hypothyroid, and others remain euthyroid [<a href="#rid37">37</a>]. Sometimes thyroid eye disease occurs in patients with hypothyroidism (high TSH, low free T4) due to classical chronic autoimmune thyroiditis (Hashimoto's disease), and these patients may have stimulating TSH receptor (TSHR) antibodies but inadequate thyroid reserve [<a href="#rid38">38</a>].</p><p>There is usually a temporal relationship between the thyroid eye disease and the onset of hyperthyroidism. The eye involvement appears before the onset of hyperthyroidism in approximately 20 percent of patients, concurrently in approximately 40 percent, and in the six months after diagnosis in approximately 20 percent [<a href="#rid39">39</a>]. In the remainder, the eye disease first becomes apparent after treatment of the hyperthyroidism, more often in patients treated with radioiodine. (See  <a class="medical medical_review" href="/z/d/html/7827.html" rel="external">"Treatment of thyroid eye disease", section on 'Reversal of hyperthyroidism, if present'</a>.)</p><p class="headingAnchor" id="H3847024961"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In most patients, the diagnosis of thyroid eye disease is obvious because of the combination of the characteristic ocular abnormalities (proptosis, periorbital edema)  (<a class="graphic graphic_picture graphicRef116687" href="/z/d/graphic/116687.html" rel="external">picture 2</a>) and hyperthyroidism. It is, however, important to differentiate the eye signs of thyroid eye disease from the nonspecific eye signs of thyroid hormone excess, including lid lag and stare (due to enhanced contraction of the levator palpebrae muscles of the eyelids) without proptosis. The stare may give the appearance of proptosis, when none in fact exists. These signs alone do not indicate the presence of thyroid eye disease and may subside when the hyperthyroidism is treated.</p><p>Unilateral thyroid eye disease may be considerably more difficult to diagnose in the absence of thyroid dysfunction and must be differentiated from space-occupying lesions of the orbit, typically with CT (without contrast) or MRI of the orbits. Imaging is also performed in patients with moderate to severe thyroid eye disease to assess the risk of complications (eg, crowding of the optic nerve at the orbital apex), and it is sometimes helpful in the differential diagnosis or in planning for surgery. (See <a class="local">'Imaging'</a> below.)</p><p class="headingAnchor" id="H782238643"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Eye signs simulating thyroid eye disease can also be present in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Orbital cellulitis. (See  <a class="medical medical_review" href="/z/d/html/3414.html" rel="external">"Orbital cellulitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orbital myositis. (See  <a class="medical medical_review" href="/z/d/html/5238.html" rel="external">"Overview of diplopia", section on 'Orbital myositis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histiocytosis. (See  <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myasthenia gravis. (See  <a class="medical medical_review" href="/z/d/html/5242.html" rel="external">"Ocular myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orbital tumors, including metastatic tumors to the orbit. (See  <a class="medical medical_review" href="/z/d/html/5226.html" rel="external">"Optic pathway glioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced ocular muscle myopathy. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of a patient with thyroid eye disease includes laboratory assessment (if not already available), examination of the eyes, and assessment of disease activity and severity.</p><p class="headingAnchor" id="H3547627351"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Thyroid function tests will have already been obtained in most patients. If not available, we measure:</p><p class="bulletIndent1"><span class="glyph">●</span>TSH</p><p class="bulletIndent1"><span class="glyph">●</span>Free T4</p><p class="bulletIndent1"><span class="glyph">●</span>Total T3</p><p class="bulletIndent1"><span class="glyph">●</span>TSH receptor (TSHR) antibodies</p><p></p><p>Measurement of serum TSHR antibodies can be helpful in confirming an obvious or less than obvious diagnosis and helps assess the severity of the condition and monitoring the patient's response to treatment [<a href="#rid27">27,40</a>].</p><p class="headingAnchor" id="H467486008"><span class="h2">Eye examination</span><span class="headingEndMark"> — </span>The classification of disease severity (mild, moderate, severe, sight threatening)  (<a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">table 1</a>) and activity  (<a class="graphic graphic_table graphicRef116361" href="/z/d/graphic/116361.html" rel="external">table 2</a>) is based on elements of the eye examination (see <a class="local">'Assessment of disease severity and activity'</a> below). A multidisciplinary approach is recommended with early consultation and comanagement with ophthalmology in all patients with moderate-severe disease.</p><p>Physical examination of the eyes of a patient with thyroid eye disease should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inspection of the conjunctivae and periorbital tissue, looking for conjunctival injection and edema (chemosis) and periorbital edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determination of the extent to which the upper and lower lids can be closed, because failure of apposition promotes drying and ulceration of the cornea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of the range of motion of the eyes. Impairment of extraocular muscle function is often evident by the finding of dysconjugate gaze during extraocular muscle movement testing. Dysconjugate gaze may lead to double vision, initially on extremes of gaze, and eventually in almost all directions, necessitating use of prism lenses or an eye patch, while awaiting stable fibrosis of the eye muscles before attempting corrective eye muscle (strabismus) surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Objective measurements of the degree of proptosis, using an exophthalmometer. These instruments permit measurement of the distance between the lateral angle of the bony orbit and an imaginary line tangent to the most anterior part of the cornea. The upper limit of normal is approximately 21 mm in White, 24 mm in Black, and 19 mm in Chinese males (19, 23, and 18 mm in White, Black, and Chinese females, respectively)  (<a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">table 1</a>) [<a href="#rid41">41</a>]. The values may be as high as 30 mm in patients with severe proptosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visual acuity and color vision should be assessed by simple reading tests and color charts, and visual fields should be evaluated by confrontation.</p><p></p><p>Rare patients have extremely severe forms of orbitopathy, which can threaten vision. The forms include subluxation of the globe due to severe proptosis, ulceration or infection of the cornea secondary to an inability to close the lids, and optic neuropathy caused by compression of the optic nerve at the apex of the orbit. (See  <a class="medical medical_review" href="/z/d/html/6267.html" rel="external">"Congenital and acquired abnormalities of the optic nerve", section on 'Compression'</a>.)</p><p>The correlation between the symptoms and signs of orbitopathy is often poor. While attention to the physical findings is important in considering prognosis and therapy, it is equally important to listen to what the patient says about his or her symptoms and changes in the symptoms. A simple orbitopathy quality-of-life questionnaire has been validated to address this concern [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Assessment of disease severity and activity</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease severity</strong> – The classification of disease severity (mild, moderate, severe, sight threatening) is based on the degree of threat to vision and the severity of proptosis and soft tissue involvement  (<a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">table 1</a>) [<a href="#rid42">42-44</a>]. It is important to recognize that patients may have severe disease, such as advanced longstanding proptosis, which is no longer active based on a clinical activity score, and therefore unlikely to respond to immunomodulatory therapy. A photographic atlas of eye findings has also been developed, which may be helpful for ophthalmologic assessment [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">The older classification system, NO SPECS, with initials representing various features of thyroid eye disease, is no longer used but still included in some clinical trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease activity</strong> – Activity of disease, assessed using the clinical activity score (CAS)  (<a class="graphic graphic_table graphicRef116361" href="/z/d/graphic/116361.html" rel="external">table 2</a>), is useful for determining therapy and gauging response to that therapy [<a href="#rid43">43</a>]. Patients with a score of 3 or more are classified as having active disease and may be more likely to respond to immunomodulatory therapy, such as glucocorticoids. The CAS is also included in most clinical trials.</p><p></p><p class="bulletIndent1">The CAS can also be extended to include change over time by adding the following three criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase in proptosis (≥2 mm)</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased eye movements (≥5 degrees)</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased visual acuity (≥1 line on the Snellen eye chart)</p><p></p><p class="headingAnchor" id="H2015887697"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>In moderate to severe disease, baseline imaging of the orbits, with noncontrast CT or MRI, gives an assessment of the risk of future optic nerve compression by enlarged extraocular muscle at the orbit apex, provides an independent measurement of proptosis and orbital fat accumulation, and is sometimes helpful in the differential diagnosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>We prefer CT (without contrast) scanning because of the extensive normative data available on intraorbital volumes and the better bone visualization compared with MRI  (<a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">table 1</a> and <a class="graphic graphic_diagnosticimage graphicRef91472" href="/z/d/graphic/91472.html" rel="external">image 1</a>) [<a href="#rid45">45</a>], although MRI is being increasingly utilized in patients with thyroid eye disease. Iodinated contrast should be used with caution in patients with hyperthyroidism who are not receiving <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, since the iodine can worsen the hyperthyroidism. (See  <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction", section on 'Iodine-induced hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H4210807070"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The main autoantigen in thyroid eye disease is the thyroid-stimulating hormone (TSH) receptor (TSHR), which is expressed in orbital fibroblasts and forms a functional complex with the insulin-like growth factor 1 (IGF-1) receptor. Stimulating TSHR antibodies and activated T cells play an important role in pathogenesis of thyroid eye disease by activating orbital fibroblasts and adipocytes. The volume of both the extraocular muscles and orbital connective and adipose tissue is increased, due to inflammation, adipogenesis, and the accumulation of hydrophilic glycosaminoglycans (GAG; principally hyaluronic acid) in these tissues. GAG secretion by fibroblasts is increased by activated T cell cytokines and by the activation of the receptors for TSH and IGF-1. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Thyroid eye disease occurs in 20 to 25 percent of patients with Graves' disease. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Thyroid eye disease, like hyperthyroidism, is more common in females than males. Risk factors for the development of thyroid eye disease include smoking, prior radioiodine therapy, and possibly high serum cholesterol. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The major ocular symptoms include one or more of the following: a sense of irritation in the eyes; excessive tearing that is often made worse by exposure to cold air, wind, or bright lights; eye or retro-ocular discomfort or pain; blurring of vision; diplopia; and occasionally, loss of vision. The characteristic signs of thyroid eye disease are proptosis and periorbital edema. These findings typically occur in the setting of current or past Graves' hyperthyroidism (low TSH, high free thyroxine [T4] and/or triiodothyronine [T3]). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In most patients, the diagnosis of thyroid eye disease is obvious because of the combination of the characteristic ocular abnormalities (proptosis, periorbital edema)  (<a class="graphic graphic_picture graphicRef116687" href="/z/d/graphic/116687.html" rel="external">picture 2</a>) and hyperthyroidism. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thyroid function tests</strong> – Review prior thyroid tests. If thyroid tests are not available, measure (see <a class="local">'Laboratory'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>TSH</p><p class="bulletIndent3"><span class="glyph">-</span>Free T4</p><p class="bulletIndent3"><span class="glyph">-</span>Total T3</p><p class="bulletIndent3"><span class="glyph">-</span>TSHR antibodies</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eye examination</strong> – The classification of disease severity (mild, moderate, severe, sight threatening)  (<a class="graphic graphic_table graphicRef116360" href="/z/d/graphic/116360.html" rel="external">table 1</a>) and activity  (<a class="graphic graphic_table graphicRef116361" href="/z/d/graphic/116361.html" rel="external">table 2</a>) is based on elements of the eye examination. A multidisciplinary approach is recommended with early consultation and comanagement with ophthalmology in all patients with moderate-severe disease. (See <a class="local">'Eye examination'</a> above and <a class="local">'Assessment of disease severity and activity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – In moderate to severe disease, noncontrast CT or MRI imaging may give an assessment of the risk of future optic nerve compression by enlarged extraocular muscle at the orbital apex and is sometimes helpful in the differential diagnosis. (See <a class="local">'Imaging'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davies TF. The thyrotropin receptors spread themselves around. J Clin Endocrinol Metab 1994; 79:1232.</a></li><li><a class="nounderline abstract_t">Brenner-Gati L, Berg KA, Gershengorn MC. Thyroid-stimulating hormone and insulin-like growth factor-1 synergize to elevate 1,2-diacylglycerol in rat thyroid cells. Stimulation of DNA synthesis via interaction between lipid and adenylyl cyclase signal transduction systems. J Clin Invest 1988; 82:1144.</a></li><li><a class="nounderline abstract_t">Davies TF, Andersen S, Latif R, et al. Graves' disease. Nat Rev Dis Primers 2020; 6:52.</a></li><li><a class="nounderline abstract_t">Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362:726.</a></li><li><a class="nounderline abstract_t">Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747.</a></li><li><a class="nounderline abstract_t">Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A. Modeling Graves' Orbitopathy in Experimental Graves' Disease. Horm Metab Res 2015; 47:797.</a></li><li><a class="nounderline abstract_t">Zhang M, Ding X, Wu LP, et al. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit. Thyroid 2021; 31:638.</a></li><li><a class="nounderline abstract_t">Valyasevi RW, Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999; 84:2557.</a></li><li><a class="nounderline abstract_t">Krieger CC, Neumann S, Place RF, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. J Clin Endocrinol Metab 2015; 100:1071.</a></li><li><a class="nounderline abstract_t">Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020; 382:341.</a></li><li><a class="nounderline abstract_t">Morshed SA, Ma R, Latif R, Davies TF. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition. Thyroid 2022; 32:429.</a></li><li><a class="nounderline abstract_t">Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75:222.</a></li><li><a class="nounderline abstract_t">Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994; 93:2738.</a></li><li><a class="nounderline abstract_t">Wall JR, Salvi M, Bernard NF, et al. Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders. Immunol Today 1991; 12:150.</a></li><li><a class="nounderline abstract_t">Lee HJ, Stefan-Lifshitz M, Li CW, Tomer Y. Genetics and epigenetics of autoimmune thyroid diseases: Translational implications. Best Pract Res Clin Endocrinol Metab 2023; 37:101661.</a></li><li><a class="nounderline abstract_t">Yin X, Latif R, Bahn R, Davies TF. Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy. Thyroid 2012; 22:730.</a></li><li><a class="nounderline abstract_t">Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 98:1443.</a></li><li><a class="nounderline abstract_t">Perros P, Hegedüs L, Bartalena L, et al. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 2017; 12:72.</a></li><li><a class="nounderline abstract_t">Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbital involvement in Graves's disease. N Engl J Med 1974; 290:1447.</a></li><li><a class="nounderline abstract_t">Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80:2830.</a></li><li><a class="nounderline abstract_t">Khong JJ, Finch S, De Silva C, et al. Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. J Clin Endocrinol Metab 2016; 101:2711.</a></li><li><a class="nounderline abstract_t">Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993; 38:367.</a></li><li><a class="nounderline abstract_t">Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269:479.</a></li><li><a class="nounderline abstract_t">Szucs-Farkas Z, Toth J, Kollar J, et al. Volume changes in intra- and extraorbital compartments in patients with Graves' ophthalmopathy: effect of smoking. Thyroid 2005; 15:146.</a></li><li><a class="nounderline abstract_t">Costabel U, Bross KJ, Reuter C, et al. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986; 90:39.</a></li><li><a class="nounderline abstract_t">Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92:59.</a></li><li><a class="nounderline abstract_t">Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91:3464.</a></li><li><a class="nounderline abstract_t">Sabini E, Mazzi B, Profilo MA, et al. High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study. Thyroid 2018; 28:386.</a></li><li><a class="nounderline abstract_t">Stein JD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015; 133:290.</a></li><li><a class="nounderline abstract_t">Lanzolla G, Sabini E, Leo M, et al. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 2021; 9:733.</a></li><li><a class="nounderline abstract_t">Wiersinga WM. Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease. Endocrinol Metab (Seoul) 2016; 31:213.</a></li><li><a class="nounderline abstract_t">Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990; 150:1098.</a></li><li><a class="nounderline abstract_t">Park KS, Fung SE, Ting M, et al. Thyroid eye disease reactivation associated with COVID-19 vaccination. Taiwan J Ophthalmol 2022; 12:93.</a></li><li><a class="nounderline abstract_t">Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001; 55:283.</a></li><li><a class="nounderline abstract_t">WERNER SC. Euthyroid patients with early eye signs of Graves' disease; their responses to L-triiodothyronine and thyrotropin. Am J Med 1955; 18:608.</a></li><li><a class="nounderline abstract_t">Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 1990; 70:89.</a></li><li><a class="nounderline abstract_t">Suzuki N, Noh JY, Kameda T, et al. Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease. Clin Ophthalmol 2018; 12:739.</a></li><li><a class="nounderline abstract_t">Kahaly GJ, Diana T, Glang J, et al. Thyroid Stimulating Antibodies Are Highly Prevalent in Hashimoto's Thyroiditis and Associated Orbitopathy. J Clin Endocrinol Metab 2016; 101:1998.</a></li><li><a class="nounderline abstract_t">Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:426.</a></li><li><a class="nounderline abstract_t">Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy--stimulating antibodies. J Clin Endocrinol Metab 1998; 83:3777.</a></li><li><a class="nounderline abstract_t">Cheung JJC, Chang DL, Chan JC, et al. Exophthalmometry values in the Hong Kong Chinese adult population from a population-based study. Medicine (Baltimore) 2019; 98:e17993.</a></li><li><a class="nounderline abstract_t">Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021; 185:G43.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Barrio-Barrio J, Sabater AL, Bonet-Farriol E, et al. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol 2015; 2015:249125.</a></li><li><a class="nounderline abstract_t">Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 1986; 7:651.</a></li></ol></div><div id="topicVersionRevision">Topic 7825 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962313" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The thyrotropin receptors spread themselves around.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843569" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thyroid-stimulating hormone and insulin-like growth factor-1 synergize to elevate 1,2-diacylglycerol in rat thyroid cells. Stimulation of DNA synthesis via interaction between lipid and adenylyl cyclase signal transduction systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32616746" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181974" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119236" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Graves' ophthalmopathy: current concepts regarding pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287396" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Modeling Graves' Orbitopathy in Experimental Graves' Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33076782" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404836" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25485727" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971679" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Teprotumumab for the Treatment of Active Thyroid Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34927457" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2784734" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201012" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1878126" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35459628" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetics and epigenetics of autoimmune thyroid diseases: Translational implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22663548" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427469" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4406684" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ultrasonographic evidence of a consistent orbital involvement in Graves's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673432" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055083" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319368" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Smoking and risk of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753674" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Volume changes in intra- and extraorbital compartments in patients with Graves' ophthalmopathy: effect of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2941248" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047020" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835285" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336220" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25502604" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34592164" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27184015" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691908" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35399967" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thyroid eye disease reactivation associated with COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589671" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14361446" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Euthyroid patients with early eye signs of Graves' disease; their responses to L-triiodothyronine and thyrotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294141" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29719374" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26964732" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Thyroid Stimulating Antibodies Are Highly Prevalent in Hashimoto's Thyroiditis and Associated Orbitopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604736" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chronology of Graves' ophthalmopathy in an incidence cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814446" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thyroid controversy--stimulating antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31764812" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Exophthalmometry values in the Hong Kong Chinese adult population from a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34297684" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351570" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088943" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
